目的 探讨采用复方红豆杉胶囊与帕博利珠单抗联合治疗晚期非小细胞肺癌的临床疗效。方法 选取唐山中心医院肿瘤科2022年10月—2024年12月收治的80例晚期非小细胞肺癌患者，按随机数字表法分为对照组和治疗组，每组40例。对照组iv帕博利珠单抗注射液，200 mg/次，每3周给药1次。治疗组在对照组的治疗基础上口服复方红豆杉胶囊，2粒/次，每日3次，21 d为1个疗程。两组给药2个疗程观察效果。观察对比两组疗效情况，比较两组生活质量量表评分（FACT-L）、卡氏功能状态量表评分（KPS）、细胞角蛋白19血清片段21-1（CYFRA21-1）、癌胚抗原（CEA）、鳞状细胞癌抗原（SCC）、糖类抗原50（CA50）水平。结果 治疗后，治疗组的总有效率（92.50%）高于对照组（75.00%）（P＜0.05）。治疗后，与对照组对比，治疗组患者出现胸闷、咳嗽、胸痛、痰中带血症状缓解时间均较短（P＜0.05）。治疗后，两组FACT-L评分、KPS评分较同组治疗前显著升高（P＜0.05）；治疗后，与对照组对比，治疗组患者FACT-L评分、KPS评分均更高（P＜0.05）。治疗后，两组CYFRA21-1、CEA、SCC、CA50水平较组内治疗前显著降低；治疗后，与对照组对比，治疗组CYFRA21-1、CEA、SCC、CA50水平均较低（P＜0.05）。结论 复方红豆杉胶囊与帕博利珠单抗协同治疗晚期非小细胞肺癌效果显著，对患者症状有较好的缓解作用，同时可以提高机体功能状况，明显改善患者生活质量，降低患者肿瘤炎性反应，值得借鉴与推广。

Objective To investigate the efficacy of Compound Hongdoushan Capsules combined with pembrolizumab in treatment of advanced non-small cell lung cancer.Methods 80 Patients with advanced non-small cell lung cancer admitted to the Department of Oncology in Tangshan Central Hospital from October 2022 to December 2024 were selected and divided into control group and treatment group according to the random number tablet method, with 40 cases in each group. Patients in control group were iv Pembrolizumab Injection, 200 mg each time, once every 3 weeks. Patients in treatment group took Compound Hongdoushan Capsules orally on the basis of control group, 2 capsules each time, 3 times daily. 21 D constituted one course of treatment. The effects were observed after two courses of administration for two groups. The therapeutic effects of two groups were observed and compared, and the levels of FACT-L score, KPS score, CYFRA21-1, CEA, SCC, and CA50 in two groups were compared.Results After treatment, the total effective rate of treatment group (92.50%) was higher than that of control group (75.00%, P < 0.05). After treatment, compared with control group, the relief time of symptoms such as chest tightness, cough, chest pain and blood in sputum in treatment group was shorter (P < 0.05). After treatment, the FACT-L scores and KPS scores of two groups were significantly increased compared with those before treatment in the same group (P < 0.05). After treatment, compared with control group, the FACT-L score and KPS score of the patients in treatment group were higher (P < 0.05). After treatment, the levels of CYFRA21-1, CEA, SCC, and CA50 in both groups were significantly lower than those before treatment within the groups. After treatment, compared with control group, the levels of CYFRA21-1, CEA, SCC and CA50 in treatment group were all lower (P < 0.05).Conclusion The combined treatment of Compound Hongdoushan Capsules and pembrolizumab has a remarkable effect in advanced non-small cell lung cancer, and has a good alleviating effect on the symptoms of patients. At the same time, it can improve the functional status of the body, significantly improve the life quality of patients, and reduce the inflammatory response of tumors in patients,which is worthy of reference and promotion.

R979.1

河北省科技计划项目（162777232）